Z51.11 reports an encounter whose reason is antineoplastic chemotherapy. Z51.12 reports an encounter whose reason is antineoplastic immunotherapy. Whichever applies is sequenced as the first-listed or principal diagnosis, and the malignancy being treated is coded second, as a secondary diagnosis — the reverse of how most cancer claims are built. Neither code has a published drug list: which one to use is a documentation call, not a lookup.
Both codes sit under category Z51 (Encounter for other aftercare and medical care) and subcategory Z51.1, “Encounter for antineoplastic chemotherapy and immunotherapy.” Per the FY2026 ICD-10-CM Tabular List, Z51 itself carries a Code also note (code also the condition requiring care) and an Excludes1 note for follow-up examination after treatment (Z08-Z09). Subcategory Z51.1 carries an Excludes2 note: “encounter for chemotherapy and immunotherapy for nonneoplastic condition — code to condition.” Neither Z51.11 nor Z51.12 individually carries its own Includes, Excludes1, Excludes2 or Code also note in the Tabular List — the only notes attach at the Z51 and Z51.1 level.
This is a high-volume question: AAPC's medical coding forum carries roughly 14 threads on Z51.11 vs Z51.12 with a combined ~77,000 views, almost all asking the same thing — how to classify a specific drug — which the official guidelines and tabular notes do not answer (see the FAQ below).
“If a patient admission/encounter is chiefly for the administration of chemotherapy, immunotherapy or external beam radiation therapy for the treatment of a neoplasm, assign code Z51.0, Encounter for antineoplastic radiation therapy, or Z51.11, Encounter for antineoplastic chemotherapy, or Z51.12, Encounter for antineoplastic immunotherapy as the first-listed or principal diagnosis. If the reason for the encounter is more than one type of antineoplastic therapy, code Z51.0 and codes from subcategory Z51.1 may be assigned together, in which case one of these codes would be reported as a secondary diagnosis. The malignancy for which the therapy is being administered should be assigned as a secondary diagnosis.”
Section I.C.2.a states the general exception this creates: the malignancy is normally the principal diagnosis for a cancer encounter, “the only exception to this guideline is if the administration of chemotherapy, immunotherapy or external beam radiation therapy is chiefly responsible for occasioning the admission/encounter” — in that one case, the Z51.-- code leads and the malignancy drops to secondary.
Section I.C.2.e.3 extends the same sequencing through a complication: when a patient whose sole reason for the encounter was chemotherapy or immunotherapy develops a complication (dehydration, neutropenic fever, nausea), the Z51.1x code stays principal, “followed by any codes for the complications.”
One case reverses it: an encounter for the insertion or implantation of radioactive elements (brachytherapy) sequences the malignancy first, and Z51.0 is not assigned at all — that guidance is specific to radiation therapy and does not extend to Z51.11 or Z51.12.
The FY2026 Tabular List gives no drug names or drug classes under either code, and the FY2026 Alphabetic Index entries are equally generic — “Chemotherapy (session) (for) → cancer → Z51.11” and “Immunotherapy (encounter for) → antineoplastic → Z51.12”, with no sub-terms for checkpoint inhibitors, monoclonal antibodies, CAR-T cell therapy or any other named class. No CMS or NCHS publication crosswalks specific drugs to one code or the other.
That gap is exactly what drives the AAPC forum traffic on this pair: a monoclonal antibody like rituximab or an immune checkpoint inhibitor like pembrolizumab could plausibly be described either way, and the guidelines leave the call to how the ordering physician documented the therapy's mechanism and intent — not to a lookup table. A commonly repeated coder heuristic (“drugs ending in ‘-mab’ are Z51.12”) is informal practice, not an official rule, and this page does not endorse it as one; treat it as a prompt to confirm with the ordering physician's documentation, not a substitute for it.
One adjacent, non-authoritative data point: elsewhere in ICD-10-CM, the poisoning/adverse-effect chapter separates T45.1 (antineoplastic and immunosuppressive drugs) from T45.A (immune checkpoint inhibitors and immunostimulant drugs) as mutually exclusive categories (each carries an Excludes1 note pointing to the other). That confirms ICD-10-CM's classification system does formally distinguish these drug classes somewhere — but that split lives in the adverse-effect chapter (T36-T50), and CMS/NCHS never cross-references it into the Z51.1 guidance, so it cannot be read as an answer key for Z51.11 vs Z51.12.
Z51.11 reports an encounter whose reason is antineoplastic chemotherapy. Z51.12 reports an encounter whose reason is antineoplastic immunotherapy. Both sit under category Z51.1, “Encounter for antineoplastic chemotherapy and immunotherapy,” and neither code carries its own Includes, Excludes1 or Excludes2 note in the FY2026 ICD-10-CM Tabular List — the distinction is which therapy was actually given, not a coding-system definition.
Z51.1x goes first when the encounter is chiefly for the chemotherapy or immunotherapy itself. Per the FY2026 ICD-10-CM Official Guidelines, Section I.C.2.e.2: “If a patient admission/encounter is chiefly for the administration of chemotherapy, immunotherapy or external beam radiation therapy for the treatment of a neoplasm, assign code Z51.0 … or Z51.11 … or Z51.12 … as the first-listed or principal diagnosis … The malignancy for which the therapy is being administered should be assigned as a secondary diagnosis.”
ICD-10-CM does not publish a drug-class list for either code. The FY2026 Tabular List and Alphabetic Index give no sub-terms under Z51.11 or Z51.12 naming specific drugs or drug classes, and no CMS or NCHS guidance crosswalks specific agents to one code or the other. The choice follows how the ordering physician documented the therapy's intent and mechanism in the record, not a lookup table — informal heuristics such as “drugs ending in ‘-mab’ are always Z51.12” are coder convention, not an official rule, and should not be treated as one.
Z51.11 (or Z51.12) still leads, followed by the complication codes. The FY2026 Guidelines, Section I.C.2.e.3, direct that when a patient admitted for the sole purpose of administering chemotherapy or immunotherapy develops a complication, the encounter code remains principal and the complication is coded secondary.
No. Category Z51.1 carries an Excludes2 note for “encounter for chemotherapy and immunotherapy for nonneoplastic condition”, directing the coder to the condition itself instead. Methotrexate for rheumatoid arthritis or rituximab for a nonneoplastic autoimmune disease is coded to the condition being treated, not to Z51.11 or Z51.12.
Both codes may be reported together. Per the FY2026 Guidelines, Section I.C.2.e.2: “If the reason for the encounter is more than one type of antineoplastic therapy, code Z51.0 and codes from subcategory Z51.1 may be assigned together, in which case one of these codes would be reported as a secondary diagnosis.” The guidelines do not specify which of Z51.11 or Z51.12 leads when both are given the same encounter — that is a documentation-driven judgment call, not a fixed rule.
All sources are publicly available federal publications. AAPC forum-thread volume is cited as evidence of reader demand, not as a source of coding rules. The methodology by which we resolve source disagreements is described in the Methodology.